Rasi Bhadramani/iStock via Getty Images Data from a phase 2 trial found that Eli Lilly's ( NYSE: LLY ) muvalaplin significntly reduced lipoprotein(a) levels at multiple doses in individuals at high risk of cardiovascular events. At the highest dose tested -- 240 mg -- the reduction was 85.8% compared to placebo at 12.
